Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, announced they entered into a supply agreement for the medical radioisotope actinium-225 (Ac-225)1.

Under the agreement, TerraPower Isotopes would supply Ratio with quantities of non-cGMP Ac-225 for use to incorporate into or use in the development of Ratio's radiopharmaceuticals.

Ac-225 plays a vital role in the development of next-generation radiopharmaceuticals, serving as a powerful alpha-emitting isotope used in targeted cancer therapies. For Ratio, access to a reliable supply of Ac-225 is essential to advancing its pipeline based on its proprietary Trillium™ and Macropa™ platforms. Together, these platforms enable the design and development of novel radiopharmaceuticals that can selectively target and eradicate cancer cells, offering a powerful and targeted approach to cancer treatment.

"Securing a reliable supply of Actinium-225 is a critical step in advancing our pipeline of targeted alpha therapies," said John Babich, Ph.D., President and Chief Scientific Officer of Ratio. "This agreement with TerraPower Isotopes strengthens our ability to scale production and advance our Trillium™ and Macropa™ platforms, which are purpose-built to fully harness the therapeutic potential of Actinium-225 in targeted alpha therapies."

"TerraPower Isotopes is committed to increasing the global supply of Actinium-225 to support cancer treatment research and development," said Scott Claunch, President of TerraPower Isotopes. "We're proud to work with Ratio Therapeutics to help realize the full potential of Actinium-225 in radiopharmaceuticals. Once linked to a disease-targeting molecule, Actinium-225 labeled drug products can be precisely delivered to cancerous tissues, where they emit high-energy alpha particles capable of destroying tumor cells while sparing surrounding healthy tissue, making it a potentially transformative treatment option for patients."